Opening discussion on the advent of differentiated thyroid cancer (DTC) and management, moderator Lori J. Wirth, MD, provides and overview of prevalence, subtypes, and prognosis.
Marcia Brose, MD, PhD, University of Pennsylvania
Advertisement
Articles by Marcia Brose, MD, PhD, University of Pennsylvania
Advertisement
Latest Updated Articles
Overview on Differentiated Thyroid Cancer (DTC)April 17th 2023
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
SERENA-6 Meets PFS2 End Point With Early Switch to Camizestrant in ER+/HER2-Negative, ESR1-Mutated Advanced Breast Cancer
5